Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 13 | 2023 | 686 | 3.720 |
Why?
|
| Hepatoblastoma | 12 | 2024 | 215 | 2.430 |
Why?
|
| Natural Killer T-Cells | 6 | 2023 | 124 | 2.290 |
Why?
|
| Liver Neoplasms | 19 | 2024 | 4557 | 1.570 |
Why?
|
| Glypicans | 3 | 2023 | 51 | 1.340 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2023 | 1146 | 1.130 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2023 | 1763 | 1.100 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2023 | 2027 | 1.000 |
Why?
|
| Receptors, Antigen | 3 | 2016 | 76 | 0.980 |
Why?
|
| Interleukin-15 | 3 | 2020 | 185 | 0.910 |
Why?
|
| Gangliosides | 3 | 2019 | 95 | 0.850 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 2576 | 0.700 |
Why?
|
| CD28 Antigens | 2 | 2016 | 202 | 0.650 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 140 | 0.620 |
Why?
|
| Interleukins | 1 | 2020 | 325 | 0.600 |
Why?
|
| Osteosarcoma | 1 | 2023 | 929 | 0.570 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 69 | 0.550 |
Why?
|
| Osteopetrosis | 1 | 2015 | 26 | 0.540 |
Why?
|
| Femoral Fractures | 1 | 2015 | 50 | 0.520 |
Why?
|
| Femur | 1 | 2015 | 158 | 0.500 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 945 | 0.490 |
Why?
|
| T-Lymphocytes | 5 | 2023 | 3869 | 0.490 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 338 | 0.490 |
Why?
|
| Immunotherapy | 4 | 2017 | 3341 | 0.480 |
Why?
|
| Ambulatory Care | 1 | 2018 | 554 | 0.480 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2023 | 675 | 0.480 |
Why?
|
| Diphosphonates | 1 | 2015 | 262 | 0.460 |
Why?
|
| Health Care Costs | 1 | 2018 | 674 | 0.450 |
Why?
|
| Child | 21 | 2023 | 29154 | 0.440 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 1555 | 0.430 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.380 |
Why?
|
| Lymphoma, B-Cell | 2 | 2016 | 895 | 0.370 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.360 |
Why?
|
| Lymphocyte Activation | 5 | 2020 | 1688 | 0.360 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 697 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1249 | 0.310 |
Why?
|
| Child, Preschool | 14 | 2022 | 16273 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 4367 | 0.280 |
Why?
|
| Liver Transplantation | 6 | 2020 | 1112 | 0.270 |
Why?
|
| Humans | 37 | 2024 | 261506 | 0.260 |
Why?
|
| Neoplasms | 4 | 2022 | 15193 | 0.250 |
Why?
|
| Mice | 10 | 2024 | 34495 | 0.240 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 905 | 0.240 |
Why?
|
| Adolescent | 13 | 2022 | 31252 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3821 | 0.220 |
Why?
|
| Animals | 11 | 2024 | 59536 | 0.210 |
Why?
|
| Mice, SCID | 4 | 2020 | 1869 | 0.210 |
Why?
|
| SEER Program | 2 | 2022 | 1000 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 178 | 0.190 |
Why?
|
| Vincristine | 2 | 2024 | 1511 | 0.180 |
Why?
|
| Aicardi Syndrome | 1 | 2019 | 16 | 0.180 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2019 | 36 | 0.180 |
Why?
|
| Automobiles | 1 | 2019 | 9 | 0.180 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 82 | 0.170 |
Why?
|
| Neutropenia | 2 | 2020 | 968 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 266 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 342 | 0.160 |
Why?
|
| Cytokines | 3 | 2017 | 2809 | 0.160 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.160 |
Why?
|
| Male | 17 | 2021 | 123000 | 0.160 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2018 | 38 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2020 | 7226 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 15862 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 749 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 669 | 0.150 |
Why?
|
| Macrophages | 2 | 2014 | 1304 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 179 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 101 | 0.140 |
Why?
|
| Embolization, Therapeutic | 1 | 2021 | 551 | 0.140 |
Why?
|
| L-Selectin | 1 | 2016 | 34 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2020 | 479 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 327 | 0.140 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 264 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.140 |
Why?
|
| Transduction, Genetic | 2 | 2014 | 475 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 334 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2017 | 269 | 0.130 |
Why?
|
| Infant | 9 | 2023 | 13310 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 852 | 0.130 |
Why?
|
| Vidarabine | 1 | 2020 | 1341 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 5395 | 0.130 |
Why?
|
| Acetylation | 1 | 2017 | 508 | 0.130 |
Why?
|
| Cell Polarity | 1 | 2016 | 208 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2023 | 32848 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 366 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3719 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 848 | 0.130 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 15 | 0.130 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 32 | 0.120 |
Why?
|
| Female | 15 | 2020 | 141928 | 0.120 |
Why?
|
| Incidence | 2 | 2022 | 5673 | 0.120 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2013 | 10 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 403 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 864 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2019 | 574 | 0.120 |
Why?
|
| Retroviridae | 1 | 2014 | 332 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 3001 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 4988 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2019 | 998 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 328 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2016 | 577 | 0.110 |
Why?
|
| Health Personnel | 1 | 2018 | 625 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.110 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 493 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 493 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1245 | 0.100 |
Why?
|
| Parents | 1 | 2018 | 998 | 0.100 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 2238 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 851 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 446 | 0.100 |
Why?
|
| Prognosis | 6 | 2023 | 21713 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 590 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1016 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 1487 | 0.100 |
Why?
|
| Liver | 2 | 2019 | 2961 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1870 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.090 |
Why?
|
| Young Adult | 5 | 2022 | 21445 | 0.090 |
Why?
|
| Pediatrics | 1 | 2018 | 1141 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 1350 | 0.080 |
Why?
|
| Apoptosis | 2 | 2020 | 7591 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8865 | 0.080 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3230 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5178 | 0.070 |
Why?
|
| Cell Line | 1 | 2014 | 5114 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5542 | 0.070 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2992 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.070 |
Why?
|
| Hepatectomy | 2 | 2023 | 1011 | 0.070 |
Why?
|
| Sarcoma | 1 | 2016 | 1725 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2018 | 829 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2017 | 9244 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 14889 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5112 | 0.060 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 2638 | 0.060 |
Why?
|
| Mutation | 2 | 2022 | 15179 | 0.060 |
Why?
|
| Kynurenine | 1 | 2023 | 71 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 69 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 285 | 0.050 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 442 | 0.050 |
Why?
|
| Adult | 4 | 2022 | 77950 | 0.050 |
Why?
|
| Hoarseness | 1 | 2020 | 25 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 95 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 612 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 347 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 709 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10035 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13658 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 335 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2019 | 138 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8223 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2023 | 14551 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 984 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 6915 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 256 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 1021 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1022 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 846 | 0.030 |
Why?
|
| Recurrence | 1 | 2023 | 4758 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 284 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 1960 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2023 | 1443 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1375 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2803 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1681 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 383 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 39 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2012 | 173 | 0.030 |
Why?
|
| Middle Aged | 1 | 2018 | 86204 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 328 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1225 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 1082 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2017 | 2358 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 3045 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 6682 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3981 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 1519 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6207 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5637 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 2796 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1538 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 5710 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 2738 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 12873 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 2979 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 2466 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 6311 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17523 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 8873 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 6550 | 0.010 |
Why?
|